Abstract
Background: Histone deacetylases (HDACs) play key roles in many biological phenomena and HDAC inhibition has been proved to be an effective strategy in cancer therapy. Over the last few decades, a plethora of structurally diverse HDAC inhibitors have been reported for a broad range of tumor indications. Among them, macrocyclic HDAC inhibitors, including cyclic peptides, depsipeptides and peptidomimetics, etc., have drawn lots of interests because of the fact that macrocyclic HDAC inhibitors have the potential for member or isoform selective inhibition.
Conclusion: Macrocyclic HDAC inhibitors present an excellent opportunity for the selective modulation of HDAC inhibitors due to their complex recognition cap group moieties. However, compared with the structurally simpler synthetic HDAC inhibitors, efforts to develop macrocyclic HDAC inhibitors have been so far modestly successful with only one compound (romidepsin) approved for the cancer treatment. Development of macrocyclic HDAC inhibitors are hampered by the complex reaction schemes required for their synthesis. We expect that in the near future, more macrocyclic HDAC inhibitors will be identified from natural products; and further modification or SAR studies will be made on these or already known natural macrocyclic HDAC inhibitors. More selective drug-like macrocyclic HDAC inhibitors will be designed and identified after understanding the interactions between the ligand and the HDACs.
Keywords: Histone Deacetylases Inhibitor (HDAC), macrocycle, drug development, drug design, selectivity.
Current Medicinal Chemistry
Title:Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Volume: 24 Issue: 37
Author(s): Kai Cheng, Siyu Li and Chenzhong Liao*
Affiliation:
- School of Biological and Medical Engineering, Hefei University of Technology, Hefei 230009,China
Keywords: Histone Deacetylases Inhibitor (HDAC), macrocycle, drug development, drug design, selectivity.
Abstract: Background: Histone deacetylases (HDACs) play key roles in many biological phenomena and HDAC inhibition has been proved to be an effective strategy in cancer therapy. Over the last few decades, a plethora of structurally diverse HDAC inhibitors have been reported for a broad range of tumor indications. Among them, macrocyclic HDAC inhibitors, including cyclic peptides, depsipeptides and peptidomimetics, etc., have drawn lots of interests because of the fact that macrocyclic HDAC inhibitors have the potential for member or isoform selective inhibition.
Conclusion: Macrocyclic HDAC inhibitors present an excellent opportunity for the selective modulation of HDAC inhibitors due to their complex recognition cap group moieties. However, compared with the structurally simpler synthetic HDAC inhibitors, efforts to develop macrocyclic HDAC inhibitors have been so far modestly successful with only one compound (romidepsin) approved for the cancer treatment. Development of macrocyclic HDAC inhibitors are hampered by the complex reaction schemes required for their synthesis. We expect that in the near future, more macrocyclic HDAC inhibitors will be identified from natural products; and further modification or SAR studies will be made on these or already known natural macrocyclic HDAC inhibitors. More selective drug-like macrocyclic HDAC inhibitors will be designed and identified after understanding the interactions between the ligand and the HDACs.
Export Options
About this article
Cite this article as:
Cheng Kai, Li Siyu and Liao Chenzhong*, Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer, Current Medicinal Chemistry 2017; 24 (37) . https://dx.doi.org/10.2174/0929867324666170209105315
DOI https://dx.doi.org/10.2174/0929867324666170209105315 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice
Anti-Cancer Agents in Medicinal Chemistry NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery The Sphingolipid Rheostat: A Potential Target for Improving Pancreatic Islet Survival and Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Gut Microbiota in Human Health and Diseases
Current Nutrition & Food Science MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Some Personal Memories of Bob Chanock
Infectious Disorders - Drug Targets The Influence of Erythropoietin and Proinflammatory Cytokines in the Development of Cerebral Palsy
Vascular Disease Prevention (Discontinued) Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Green Reduction of Graphene Oxide into Graphene by Cow Urine
Current Nanomaterials Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Semi-dynamic Control of FCM Initialization for Automatic Extraction of Inflamed Appendix from Ultrasonography
Current Medical Imaging Caffeic Acid, A Versatile Pharmacophore: An Overview
Mini-Reviews in Medicinal Chemistry Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Investigation of the Antiproliferative Action of the Quinoline Alkaloids Kokusaginine and Skimmianine on Human Cell Lines
Current Signal Transduction Therapy Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1
Anti-Cancer Agents in Medicinal Chemistry Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?
Clinical Cancer Drugs